Drug Approval | December 26, 2025
Japan nod to Dupixent for children with severe asthma
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Subscribe To Our Newsletter & Stay Updated
